IPO - Sonnet BioTherapeutics Holdings, Inc.

Form Type: S-1/A

Filing Date: 2025-01-30

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225004302

Filing Summary: On January 30, 2025, Sonnet BioTherapeutics Holdings, Inc. filed an amendment to its Form S-1 registration statement for an initial public offering (IPO). This amendment includes information regarding the resale of shares by selling stockholders and details about the issuance of shares upon the exercise of warrants. The company is conducting a resale offering of 127,500 shares of common stock, alongside 545,500 shares issuable from pre-funded warrants and 1,758,325 shares from common warrants. These shares were originally issued in private placements on December 10, 2024. The total gross proceeds to Sonnet from earlier offerings amount to approximately $3.9 million. The document highlights the planned delay in the effectiveness of the registration and includes risks associated with investment in their securities. Also noted are recent reverse stock splits carried out on September 30, 2024, and prior dates, affecting the outstanding common stock. The company's common stock trades on The Nasdaq under the symbol 'SONN.'

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-30

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225004303

Filing Summary: On January 30, 2025, Sonnet BioTherapeutics Holdings, Inc. filed an amendment to its registration statement on Form S-1 with the SEC to register for potential resale of up to 2,000,000 shares of its common stock by the selling securityholder, Chardan Capital Markets LLC. This amendment indicates the company's ongoing equity financing strategy, involving issuance of common stock under a Purchase Agreement with Chardan. The document outlines prior sales under this agreement and provides details about the number of shares to be issued, use of proceeds, risk factors associated with the investment in the company's securities, and the history of reverse stock splits, highlighting the company's efforts to align its share structure and enhance market conditions for its stock. The company stated that it will not receive any proceeds from the shares sold by Chardan, but anticipates that the total gross proceeds from potential sales could reach $25 million, depending on market conditions at the time of sale. Important regulatory and operational details are also included alongside the risks related to the financing structure and stock performance post-offering.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-22

Corporate Action: Ipo

Type: New

Accession Number: 000149315225003230

Filing Summary: On January 22, 2025, Sonnet BioTherapeutics Holdings, Inc. filed an S-1 registration statement under the Securities Act of 1933. This action is part of their intention to publicly offer shares of their common stock. The statement includes details of a proposed sale to the public, with shares being sold from time to time after the registration becomes effective. The company has included information about the securities offered, including 127,500 shares of common stock and shares issuable from outstanding warrants. The prospectus outlines both risk factors and the use of proceeds as intended for research, development, and working capital. Notably, the company conducted a reverse stock split on multiple occasions prior to this filing, adjusting share values and amounts accordingly. The registration is in compliance with the Securities and Exchange Commission's regulations, emphasizing the associated risks of investing, including a lack of operating history and dependency on achieving clinical and regulatory milestones. The last recorded market price for their common stock prior to the filing was $1.54, with common stock trading on Nasdaq under the symbol 'SONN'.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-22

Corporate Action: Ipo

Type: New

Accession Number: 000149315225003232

Filing Summary: Sonnet BioTherapeutics Holdings, Inc. filed a registration statement on Form S-1 with the SEC on January 22, 2025, regarding the proposed sale of up to 2,000,000 shares of its Common Stock by Chardan Capital Markets LLC. The offering is conducted under a committed equity facility established via a Purchase Agreement signed on May 2, 2024. As of January 17, 2025, the company issued 4,706 shares for net proceeds of $0.1 million. The proceeds are intended for research and development, including clinical trials, working capital, and other general corporate purposes. The last quoted sale price for its Common Stock on January 17, 2025, was $1.54. The document notes a significant reverse stock split affecting the Common Stock, with details on prior stock splits listed. Investors are cautioned about the volatility of share prices and risks associated with the investment in these securities.

Document Link: View Document